Major Depressive Disorder News and Research

RSS
Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.
Future-Directed Therapy for patients with major depression

Future-Directed Therapy for patients with major depression

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

High consumption of caffeinated coffee appears to reduce risk of depression in women

High consumption of caffeinated coffee appears to reduce risk of depression in women

Researchers discover molecular-level changes in brains of women with major depressive disorder

Researchers discover molecular-level changes in brains of women with major depressive disorder

Longer looks: Unknowns in sports medicine; shackling pregnant prisoners

Longer looks: Unknowns in sports medicine; shackling pregnant prisoners

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

Dad's stress can affect unborn children

Dad's stress can affect unborn children

Daily exercise can work as well as second antidepressant drug

Daily exercise can work as well as second antidepressant drug

Mood-related brain protein linked to sadness during cigarette withdrawal

Mood-related brain protein linked to sadness during cigarette withdrawal

Positive results from levomilnacipran Phase III study for major depressive disorder

Positive results from levomilnacipran Phase III study for major depressive disorder

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

People with long term debilitating physical illness demonstrate mental resilience

People with long term debilitating physical illness demonstrate mental resilience

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

People with long term debilitating physical illness demonstrate mental resilience

People with long term debilitating physical illness demonstrate mental resilience

Early life adversity and prior depressive episodes make people become depressed more easily

Early life adversity and prior depressive episodes make people become depressed more easily

Simple non-invasive breath test could accurately detect vitamin B12 deficiency

Simple non-invasive breath test could accurately detect vitamin B12 deficiency

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Naurex commences GLYX-13 Phase II trial in treatment-resistant depression

Naurex commences GLYX-13 Phase II trial in treatment-resistant depression

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.